A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Merck Sharp & Dohme LLC
MOMA Therapeutics
Artios Pharma Ltd
Seagen Inc.
SN BioScience
Toray Industries, Inc
PharmaMar
Jiangsu Hansoh Pharmaceutical Co., Ltd.
EpicentRx, Inc.
Agenus Inc.
Daiichi Sankyo
Pfizer